Dermapharm Holding SE (DMPG)

Currency in EUR
32.75
-0.70(-2.09%)
Closed·
Trading near 52-week Low
DMPG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.7533.45
52 wk Range
32.7551.90
Key Statistics
Prev. Close
32.75
Open
32.95
Day's Range
32.75-33.45
52 wk Range
32.75-51.9
Volume
42.48K
Average Volume (3m)
33.13K
1-Year Change
-7.6164%
Book Value / Share
11.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DMPG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
51.00
Upside
+55.73%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Dermapharm Holding SE News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 51.00
(+55.73% Upside)

Dermapharm Holding SE Earnings Call Summary for Q3/2026

  • Q3 sales flat YoY; 9-month revenue up 1.7% to €884M as branded-product growth slowed sharply to 1.7% from 12% in Q2, weighing on shares.
  • Stock fell 7.12% to $35.85 on weaker momentum despite strong cash metrics; operating cash flow rose 10%, free cash flow up 17% in 9 months.
  • Management confirmed full-year 2026 guidance, expects leverage below 3.0x adjusted EBITDA by year-end despite Q3 organic growth turning negative.
  • Q4 must improve to meet annual targets; company banking on seasonal allergy demand, international expansion, and Arkopharma B2B2C repositioning.
  • Adjusted EBITDA declined €3M in Q3 on lower BioNTech contribution; regulatory pressure on cannabis and supplements remains a headwind to growth.
Last Updated: 2026-11-12, 08:40 a/m
Read Full Transcript

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
0.52 / --
Revenue / Forecast
293.4M / 305M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.52
Dividend Yield
2.69%
Industry Median 2.02%
Annualized payout
0.88
Paid unevenly
5-Years Growth
-
Growth Streak

DMPG Income Statement

Compare DMPG to Peers and Sector

Metrics to compare
DMPG
Peers
Sector
Relationship
P/E Ratio
12.4x24.4x−0.2x
PEG Ratio
0.730.020.00
Price/Book
2.9x2.4x2.6x
Price / LTM Sales
1.4x2.7x2.6x
Upside (Analyst Target)
55.7%14.5%76.9%
Fair Value Upside
Unlock11.0%14.9%Unlock

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.

Employees
3503
Market
Germany

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.10M3.90%71.58M
Other Institutional Investors
44.42M82.51%1.51B
Public Companies & Retail Investors
7.31M13.58%249.04M
Total
53.84M100.00%1.83B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Themis Beteiligungs-AG79.50%42,801,0001,457,374
Mawer Investment Management Ltd.2.97%1,599,72854,471

People Also Watch

10.84
GLJn
-4.24%
42.500
FIEG
+0.47%
14.480
EUZG
-1.83%
54.100
NEKG
-3.31%
57.450
GBFG
-3.69%

FAQ

What Is the Dermapharm (DMPG) Stock Price Today?

The Dermapharm stock price today is 32.75 EUR.

What Stock Exchange Does Dermapharm Trade On?

Dermapharm is listed and trades on the Frankfurt Stock Exchange.

What Is the Stock Symbol for Dermapharm?

The stock symbol for Dermapharm is "DMPG."

Does Dermapharm Pay Dividends? What’s The Current Dividend Yield?

The Dermapharm dividend yield is 2.7%%.

What Is the Dermapharm Market Cap?

As of today, Dermapharm market cap is 1.62B EUR.

What Is Dermapharm's Earnings Per Share (TTM)?

The Dermapharm EPS (TTM) is 2.52.

When Is the Next Dermapharm Earnings Date?

Dermapharm will release its next earnings report on Apr 14, 2027.

From a Technical Analysis Perspective, Is DMPG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Dermapharm Stock Split?

Dermapharm has split 0 times.

How Many Employees Does Dermapharm Have?

Dermapharm has 3503 employees.

What is the current trading status of Dermapharm (DMPG)?

As of Nov 21, 2026, Dermapharm (DMPG) is trading at a price of 32.75 EUR, with a previous close of 32.75 EUR. The stock has fluctuated within a day range of 32.75 EUR to 33.45 EUR, while its 52-week range spans from 32.75 EUR to 51.90 EUR.

What Is Dermapharm (DMPG) Price Target According to Analysts?

The average 12-month price target for Dermapharm is 51.00 EUR, with a high estimate of 60 EUR and a low estimate of 44 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +55.73% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.